State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

SOHO 2023: CML - Are We Doing It Right?

SOHO 2023 Eleventh Annual Meeting

J. Cortés

SOHO 2023: Rational TKI Choice in CML

SOHO 2023 Eleventh Annual Meeting

M. Deininger

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry

Treating CML Patients With TKI Resistance vs. TKI Intolerance

The University of Alabama at Birmingham School of Medicine

O. Jamy

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone…

Insights from 2023 ASH Annual Meeting

M. Luskin

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Understanding and Addressing the Challenges in CML in 2024

Indy Hematology Review

R. Larson

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

Akriti Jain

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib an…

Insights from 2023 ASH Annual Meeting

E. Jabbour